MX2022015525A - Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos. - Google Patents
Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos.Info
- Publication number
- MX2022015525A MX2022015525A MX2022015525A MX2022015525A MX2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A
- Authority
- MX
- Mexico
- Prior art keywords
- cyclohexyl
- ylsulfanyl
- ureido
- thiazol
- propoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063035996P | 2020-06-08 | 2020-06-08 | |
| PCT/US2021/036084 WO2021252311A1 (en) | 2020-06-08 | 2021-06-07 | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015525A true MX2022015525A (es) | 2023-03-23 |
Family
ID=78845832
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015525A MX2022015525A (es) | 2020-06-08 | 2021-06-07 | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos. |
| MX2025012175A MX2025012175A (es) | 2020-06-08 | 2022-12-06 | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxiciclohexil)ureido]tiazol-5-ilsulfanil}-acetico y usos de los mismos |
| MX2025012174A MX2025012174A (es) | 2020-06-08 | 2022-12-06 | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxiciclohexil)ureido]tiazol-5-ilsulfanil}-acetico y usos de los mismos |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025012175A MX2025012175A (es) | 2020-06-08 | 2022-12-06 | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxiciclohexil)ureido]tiazol-5-ilsulfanil}-acetico y usos de los mismos |
| MX2025012174A MX2025012174A (es) | 2020-06-08 | 2022-12-06 | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxiciclohexil)ureido]tiazol-5-ilsulfanil}-acetico y usos de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12479808B2 (enExample) |
| EP (1) | EP4161640A4 (enExample) |
| JP (1) | JP2023530786A (enExample) |
| KR (1) | KR20230048502A (enExample) |
| CN (2) | CN116194442A (enExample) |
| AU (1) | AU2021289309A1 (enExample) |
| CA (1) | CA3181722A1 (enExample) |
| MX (3) | MX2022015525A (enExample) |
| WO (1) | WO2021252311A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019287437A1 (en) | 2018-06-12 | 2020-09-10 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| CN116194442A (zh) | 2020-06-08 | 2023-05-30 | 维特卫治疗有限责任公司 | {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB771147A (en) | 1954-06-04 | 1957-03-27 | Merck & Co Inc | Derivatives of urea |
| ZA6706928B (enExample) | 1967-03-23 | |||
| CH493195A (de) | 1968-01-23 | 1970-07-15 | Ciba Geigy | Schädlingsbekämpfungsmittel |
| GB1195672A (en) | 1968-02-01 | 1970-06-17 | Mobil Oil Corp | Novel Urea Derivatives and Herbicides containing the same |
| CH498859A (de) | 1968-07-17 | 1970-11-15 | Agripat Sa | Verfahren zur Herstellung von Thiadiazolyl-harnstoffen |
| GB1318291A (en) | 1970-04-15 | 1973-05-23 | Shell Int Research | Carboxamide derivatives and fungicidal compositions containing them |
| NL7106557A (enExample) | 1970-06-15 | 1971-12-17 | ||
| IL72093A0 (en) | 1983-06-20 | 1984-10-31 | Lilly Co Eli | N'-substituted(3-alkyl-5-isothiazolyl)urea derivatives |
| IE68593B1 (en) | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US6579314B1 (en) | 1995-03-10 | 2003-06-17 | C.R. Bard, Inc. | Covered stent with encapsulated ends |
| CA2247286A1 (en) | 1996-02-26 | 1997-08-28 | Hirohiko Hasegawa | Sulfonylureidopyrazole derivatives |
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| EP0979823B1 (en) | 1997-11-14 | 2006-03-29 | Kowa Company Ltd. | Novel amide compounds and drugs containing the same |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| CN1332726A (zh) | 1998-11-02 | 2002-01-23 | 卫福有限公司 | 吡咯烷化合物及其药物用途 |
| JP2002539119A (ja) | 1999-03-08 | 2002-11-19 | バイエル アクチェンゲゼルシャフト | チアゾリルウレア誘導体および抗ウイルス剤としてのそれらの使用 |
| CZ301366B6 (cs) | 1999-03-29 | 2010-02-03 | F. Hoffmann-La Roche Ag | 2-Fenyl-3-cykloalkylpropionamidová sloucenina, zpusob její prípravy a farmaceutický prostredek s jejím obsahem |
| US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US6503949B1 (en) | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
| JP2003503350A (ja) | 1999-06-30 | 2003-01-28 | 第一製薬株式会社 | Ｖｌａ−４インヒビター化合物 |
| US6806230B1 (en) | 1999-09-09 | 2004-10-19 | Kumiai Chemical Industry Co., Ltd. | Pyrimidine derivatives and herbicides containing them |
| US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
| WO2001057008A1 (en) | 2000-02-07 | 2001-08-09 | Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| US6608038B2 (en) | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| CA2407416C (en) | 2000-05-03 | 2006-07-18 | Paige Erin Mahaney | Alkynyl phenyl heteroaromatic glucokinase activators |
| AU5227001A (en) | 2000-05-03 | 2001-11-12 | Hoffmann La Roche | Hydantoin-containing glucokinase activators |
| EP1282611B1 (en) | 2000-05-08 | 2004-10-20 | F. Hoffmann-La Roche Ag | Substituted phenylacetamides and their use as glucokinase activators |
| DK1283830T3 (da) | 2000-05-08 | 2008-08-25 | Hoffmann La Roche | Para-amin-substituerede phenylamidglucokinase-aktivatorer |
| PT1305301E (pt) | 2000-07-20 | 2005-09-30 | Hoffmann La Roche | Benzeno-acetamidas alfa-acilo e alfa-heteroatomo-substituidas activadoras da glucocinase |
| US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| US20020173507A1 (en) | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
| WO2002046173A1 (en) | 2000-12-06 | 2002-06-13 | F. Hoffmann-La Roche Ag | Fused heteroaromatic glucokinase activators |
| UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| US6881746B2 (en) | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
| WO2003055482A1 (en) | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Amide derivatives as gk activators |
| AU2003243921B2 (en) | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| MXPA05009059A (es) | 2003-02-26 | 2005-10-19 | Banyu Pharma Co Ltd | Derivados de heteroarilcarbamoilbenceno. |
| US7111188B2 (en) | 2003-07-31 | 2006-09-19 | International Business Machines Corporation | Dynamically configurable fault tolerance in autonomic computing with multiple service points |
| PT1723128E (pt) | 2004-01-06 | 2013-02-27 | Novo Nordisk As | Heteroaril-ureias e o seu uso como activadores da glicoquinase |
| US20070147220A1 (en) | 2004-02-26 | 2007-06-28 | Koninklijke Philips Electronics, N.V. | Multiple-spiral hybrid disc for e-book applications |
| WO2005103050A2 (en) | 2004-04-02 | 2005-11-03 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of rock and other protein kinases |
| JP2008502658A (ja) | 2004-06-17 | 2008-01-31 | ノボ ノルディスク アクティーゼルスカブ | 肝臓選択的グルコキナーゼ活性化因子の使用 |
| WO2006037233A1 (en) | 2004-10-07 | 2006-04-13 | Stem Cell Therapeutics Corp. | Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds |
| US20060246141A1 (en) | 2005-04-12 | 2006-11-02 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
| US20100028439A1 (en) | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| JP2009500378A (ja) | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー／エス | グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素 |
| KR20080024211A (ko) | 2005-07-08 | 2008-03-17 | 노보 노르디스크 에이/에스 | 디시클로알킬 우레아 글루코키나제 활성제 |
| BRPI0612996A2 (pt) | 2005-07-14 | 2010-12-14 | Novo Nordisk As | ativadores de urÉia glucocinase |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| US8138185B2 (en) | 2007-01-09 | 2012-03-20 | Novo Nordisk A/S | Urea glucokinase activators |
| AU2008204530B2 (en) | 2007-01-11 | 2013-08-01 | Vtv Therapeutics Llc | Urea glucokinase activators |
| WO2009054251A1 (ja) | 2007-10-25 | 2009-04-30 | Sanyo Electric Co., Ltd. | 発電装置 |
| EA018988B1 (ru) | 2008-05-16 | 2013-12-30 | Такеда Калифорния, Инк. | Активаторы глюкокиназы |
| NZ603614A (en) | 2010-05-26 | 2014-10-31 | Transtech Pharma Llc | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
| EP2392575A1 (en) | 2010-06-04 | 2011-12-07 | LEK Pharmaceuticals d.d. | A novel synthetic approach to ß-aminobutyryl substituted compounds |
| CN118453592A (zh) | 2012-05-17 | 2024-08-09 | Vtv治疗有限责任公司 | 用于治疗糖尿病的葡萄糖激酶活化剂组合物 |
| AU2014226292B2 (en) | 2013-03-04 | 2018-10-04 | Vtv Therapeutics Llc | Solid compositions comprising a glucokinase activator and methods of making and using the same |
| WO2014137797A2 (en) | 2013-03-04 | 2014-09-12 | Transtech Pharma, Llc | Stable glucokinase activator compositions |
| JP6102611B2 (ja) | 2013-07-31 | 2017-03-29 | セイコーエプソン株式会社 | 液体噴射装置及びワイピング方法 |
| CN109646404B (zh) | 2016-12-15 | 2022-10-04 | 华领医药技术（上海）有限公司 | 葡萄糖激酶激活剂的口服制剂及其制备方法 |
| AU2019287437A1 (en) | 2018-06-12 | 2020-09-10 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| CN121202809A (zh) | 2020-06-08 | 2025-12-26 | 维特卫治疗有限责任公司 | {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 |
| CN116194442A (zh) | 2020-06-08 | 2023-05-30 | 维特卫治疗有限责任公司 | {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途 |
-
2021
- 2021-06-07 CN CN202180056620.5A patent/CN116194442A/zh active Pending
- 2021-06-07 KR KR1020237000610A patent/KR20230048502A/ko active Pending
- 2021-06-07 JP JP2023519157A patent/JP2023530786A/ja active Pending
- 2021-06-07 CN CN202511838345.9A patent/CN121591674A/zh active Pending
- 2021-06-07 WO PCT/US2021/036084 patent/WO2021252311A1/en not_active Ceased
- 2021-06-07 MX MX2022015525A patent/MX2022015525A/es unknown
- 2021-06-07 CA CA3181722A patent/CA3181722A1/en active Pending
- 2021-06-07 US US18/000,907 patent/US12479808B2/en active Active
- 2021-06-07 AU AU2021289309A patent/AU2021289309A1/en active Pending
- 2021-06-07 EP EP21822587.8A patent/EP4161640A4/en active Pending
-
2022
- 2022-12-06 MX MX2025012175A patent/MX2025012175A/es unknown
- 2022-12-06 MX MX2025012174A patent/MX2025012174A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3181722A1 (en) | 2021-12-16 |
| EP4161640A1 (en) | 2023-04-12 |
| MX2025012175A (es) | 2025-11-03 |
| AU2021289309A1 (en) | 2023-01-19 |
| WO2021252311A1 (en) | 2021-12-16 |
| US20230219909A1 (en) | 2023-07-13 |
| JP2023530786A (ja) | 2023-07-19 |
| CN116194442A (zh) | 2023-05-30 |
| CN121591674A (zh) | 2026-03-03 |
| KR20230048502A (ko) | 2023-04-11 |
| US12479808B2 (en) | 2025-11-25 |
| EP4161640A4 (en) | 2024-01-17 |
| MX2025012174A (es) | 2025-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025012174A (es) | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxiciclohexil)ureido]tiazol-5-ilsulfanil}-acetico y usos de los mismos | |
| EP4491199A3 (en) | Gadolinium bearing pcta-based contrast agents | |
| CY1119076T1 (el) | Αλατα πιπεραζινης ως ανταγωνιστες των d3/d2 | |
| AR031944A1 (es) | Sal de fosfato del inhibidor de la oxido nitrico sintasa | |
| MY131525A (en) | Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors | |
| TN2009000459A1 (en) | Metabolites of (thio) carbamoyl-cyclohexane derivatives | |
| NO155805C (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter. | |
| PT998473E (pt) | Modificacao da forma de cristal de um derivado de n-fenil-2-pirimidinoamina processos para a sua preparacao e sua utilizacao | |
| DE60234028D1 (de) | Hydantion-derivate als hemmer von matrix-metalloproteinasen | |
| CL2024000758A1 (es) | Sal de trometamina de ácido 2-[4-[(5,6-difenilpirazin-2-il)-propan-2-ilamino]butoxi]acético | |
| CY1110358T1 (el) | Υποκατεστημενα παραγωγα προπενυλ πιπεραζινης ως νεοι αναστολεις της αποακετυλασης ιστονης | |
| ZA202213152B (en) | Novel acid secretion inhibitor and use thereof | |
| EA200971086A1 (ru) | Фармацевтические композиции и способ лечения шизофрении | |
| MX2021010906A (es) | Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas. | |
| PE20050329A1 (es) | Derivados de nicotinamida como inhibidores de fosfodiesterasa pde4 | |
| PL431139A1 (pl) | Kompozycja farmaceutyczna bimatoprostu i tymololu | |
| DE3788373D1 (de) | Disubstituierte Piperazine. | |
| ZA202203360B (en) | Peptide amide composition and preparation method therefor | |
| MX2023003245A (es) | Derivados de amina novedosos. | |
| BRPI0607214B8 (pt) | derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação | |
| PH12021553110A1 (en) | Compounds for treating respiratory disease | |
| GB1417402A (en) | Pharmacologically active anilinobenzothiazoles | |
| HK40087135A (en) | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof | |
| CR20220644A (es) | Derivados de sulfona | |
| MX2021003375A (es) | Composiciones de rutina. |